Transcript of THE USE OF TOCILIZUMAB (ACTEMRA ® ), AN INTERLEUKIN-6 RECEPTOR ANTAGONIST, FOR THE TREATMENT OF...
- Slide 1
- THE USE OF TOCILIZUMAB (ACTEMRA ), AN INTERLEUKIN-6 RECEPTOR
ANTAGONIST, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN
METHOTREXATE REFRACTORY PATIENTS Danielle Cronin. Third -year
Pharm. D Candidate Advisor: Dr. Guffey University of Georgia
College of Pharmacy
- Slide 2
- OBJECTIVES Briefly discuss the pathophysiology of Rheumatoid
Arthritis (RA) Review the primary and secondary treatment options
for RA Discuss the role of Tocilizumab in treating RA Evaluate the
primary literature for the use of Tocilizumab when treating
patients with an inadequate response to Methotrexate (MTX)
- Slide 3
- WHAT IS RHEUMATOID ARTHRITIS? Autoimmune disease Inflammation
of joints and surrounding tissues Small joints of hands, feet,
wrists, and ankles Progressive destruction of cartilage and bone in
multiple joints
- Slide 4
- ETIOLOGY Can occur at any age More prevalent in the 7 th decade
Females Genetic predisposition HLA-DR4 or HLA-DR1 antigens Exposure
to unknown environmental factors
- Slide 5
- PATHOPHYSIOLOGY TNF, IL-1, IL-6 Schuna, Arthur. (2008)
Rheumatoid Arthritis. In Pharmacotherapy: A Pathophysiological
Approach (pp.1505-1515). New York: McGraw-Hill Companies, Inc.
- Slide 6
- PATHOPHYSIOLOGY Chronic inflammation of synovial tissue lining
the joint capsule leads to pannus formation Cartilage Synovium
Normal Knee Joint Cartilage Bone Inflamed synovial membrane Patella
Synovial fluid Femur RA Knee Joint Bone
- Slide 7
- CLINICAL PRESENTATION Signs Warm, tender, swollen joints
Symmetrical joint involvement Rheumatoid nodules
- Slide 8
- CLINICAL PRESENTATION Symptoms Joint pain and stiffness lasting
> 6 weeks Fatigue Weakness Low-grade fever Loss of appetite
Muscle pain Joint deformity late disease
- Slide 9
- CLINICAL PRESENTATION Lab Tests Rheumatoid factor Erythrocyte
sedimentation rate (ESR) C-reactive protein (CRP) Normocytic
normochromic anemia Thrombocytosis Joint fluid aspiration Turbid
due to increased WBC Joint radiographs Periarticular osteoporosis
Joint space narrowing or erosions
- Slide 10
- DIAGNOSIS CRITERIA Must have at least 4 of 7 criteria American
College of Rheumatology (ACR) 1987 Criteria Morning stiffness *
Arthritis of 3 or more joint areas * Arthritis of hand joints *
Symmetric arthritis * Rheumatoid nodules Serum rheumatoid factor
Radiographic changes * must be present for at least 6 weeks
- Slide 11
- DIAGNOSIS CRITERIA The 2010 ACR-EULAR classification criteria
for RA A Joint Involvement 1 large joint0 2-10 large joints1 1-3
small joints (with or without involvement of large joints) 2 4-10
small joints (with or without involvement of large joints) 3 >10
joints (at least 1 small joint)5 B - Serology (at least 1 test
result is needed for classification) Negative RF and negative ACPA0
Low-positive RF or low-positive ACPA2 High-positive RF or
high-positive ACPA3
- Slide 12
- DIAGNOSIS CRITERIA The 2010 ACR-EULAR classification criteria
for RA C - Acute-phase reactants (at least 1 test result is needed
for classification) Normal CRP and normal ESR0 Abnormal CRP or
abnormal ESR1 D - Duration of symptoms
- Slide 13
- GOALS OF TREATMENT Improve or maintain functional status
Controlling disease activity and joint pain Improving quality of
life Slowing destructing joint changes Complete disease
remission
- Slide 14
- NON-PHARMACOLOGIC TREATMENT Rest Occupational and physical
therapy Assistive devices Weight loss Surgery
- Slide 15
- TREATMENT OF RA 1 ST LINE Early treatment! Disease Modifying
Anti-Rheumatic Drugs (DMARD) MTX, hydroxychloroquine,
sulfasalazine, leflunomide Others less frequently used due to
toxicity and lower efficacy Low-dose oral glucocorticoids and
NSAIDS Symptomatic relief Rapid improvement while waiting for DMARD
to be effective MTX Methotrexate
- Slide 16
- TREATMENT OF RA 2 ND LINE Biologic agents Non-biologic DMARD
failure Anti-TNF agents Etanercept, Infliximab, Adalimumab IL-1
receptor antagonists Anakinra, Rituximab IL-6 receptor antagonist
Tocicluzimab Combination therapy
- Slide 17
- ACTEMRA (TOCILIZUMAB) Humanized monoclonal antibody First IL-6
receptor inhibitor Prevents signaling to inflammatory mediators
Indicated for adults with moderately to severely active RA after
failure of at least 1 tumor necrosis factor (TNF) antagonist
- Slide 18
- ACTEMRA (TOCILIZUMAB) 1 hour IV infusion every 4 weeks Starting
dose 4 mg/kg Increase to 8 mg/kg based on clinical response Black
box warning Serious infection Tuberculosis test prior to
administration
- Slide 19
- LITERATURE SEARCH PubMed Search Limits Randomized, controlled
trials Human Trials English Publication dates 2005-2010 Search
Terms Tocilizumab and Methotrexate Returned 8 results
- Slide 20
- STUDY 1
- Slide 21
- Double-Blind Randomized Controlled Clinical Trial of
Interleukin-6 Receptor Antagonist, Tocilizumab, in European
Patients With Rheumatoid Arthritis Who Had an Incomplete Response
to Methotrexate. Maini RN, Taylor PC, Szechinski J, Pavelka K,
Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson
D, Kishimoto T Arthritis & Rheumatism. 2006 Sep; 54(9):
2817-2829
- Slide 22
- OBJECTIVES Establish the safety and efficacy of repeat
infusions of Tocilizumab, a humanized IL-6 receptor antibody, alone
and in combination with MTX for the treatment of RA
- Slide 23
- SUBJECTS - INCLUSIONS N = 359 patients RA diagnosis per ACR
1987 criteria Disease duration of at least 6 months Active disease:
6 tender joints and 6 swollen joints ESR 28 mm/hrand/or CRP level
10 mg/L Inadequate response to MTX or disease flare while receiving
MTX Dose must be stabilized for at least 4 weeks prior to
study
- Slide 24
- SUBJECTS EXCLUSIONS Leukopenia Thrombocytopenia Hepatic
dysfunction AST and ALT levels > 1.5 fold ULN Significant renal
impairment DMARDs (except MTX) 4 weeks before start Anti-TNF agents
within 12 weeks Leflunomide within 6 months
- Slide 25
- METHODS Patients randomly assigned to 1 of 7 treatment groups 1
control MTX + placebo 3 monotherapy 2, 4, or 8 mg/kg Tocilizumab +
placebo 3 combination therapy 2, 4, or 8 mg/kg Tocilizumab + MTX
Tocilizumab every 4 weeks for 16 weeks MTX weekly
- Slide 26
- METHODS 359 patients randomized Toc 2 mg/kg n = 53 41 completed
Toc 4 mg/kg n = 54 43 completed Toc 8 mg/kg n = 52 44 completed Toc
2 mg/kg + MTX n = 52 46 completed Toc 4 mg/kg + MTX n = 49 42
completed Toc 8 mg/kg + MTX n = 50 43 completed MTX n = 49 40
completed
- Slide 27
- METHODS Primary end point ACR20 response at week 16 Secondary
end points ACR50 ACR70 DAS28
- Slide 28
- RESULTS - MONOTHERAPY p < 0.05
- Slide 29
- RESULTS - COMBINATION p < 0.05 p < 0.001
- Slide 30
- ** *** ** p < 0.05 *** p < 0.001
- Slide 31
- AUTHORS CONCLUSIONS Infusions of Tocilizumab every 4 weeks,
with or without background MTX therapy, produce marked and dose-
related improvement in RA disease activity 4 and 8 mg/kg doses of
Tocilizumab resulted in higher ACR50 and ACR70 responses after only
4 infusions High ACR20 response from placebo + MTX Possibly not all
MTX non-responders
- Slide 32
- LIMITATIONS Study length only 16 weeks Maximum efficacy may not
have been achieved Possibly not all patients were MTX
non-responders Funded by Roche Group
- Slide 33
- STUDY 2
- Slide 34
- Effect of Interleukin-6 Receptor Inhibition with Tocilizumab in
Patients with Rheumatoid Arthritis (OPTION Study): a double-blind,
placebo-controlled, randomized trial Smolen JS, Beaulieu A,
Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T,
Alten R The Lancet. 2008 Mar; 371:987-997
- Slide 35
- OBJECTIVE Assess the therapeutic effects of blocking IL-6 using
Tocilizumab for patients with Rheumatoid Arthritis
- Slide 36
- SUBJECTS - INCLUSIONS Adult Moderate to severe, active RA >
6 months Active RA: Swollen joint count 6 Tender joint count 8 CRP
> 10 mg/LOR ESR 28 mm/h
- Slide 37
- SUBJECTS - INCLUSIONS Methotrexate 12 weeks before Stable dose
(10-25 mg/week) 8 weeks Inadequate response to Methotrexate Active
disease NSAIDs and oral glucocorticoids permitted if on a stable
dose for 6 weeks prior
- Slide 38
- SUBJECTS - EXCLUSIONS Other autoimmune diseases or significant
systemic involvement secondary to RA Vasculitis, pulmonary
fibrosis, Feltys syndrome Functional Class IV RA Previous or
current inflammatory joint disease other than RA Currently active
or previous recurrent bacterial, viral, fungal or other
infections
- Slide 39
- SUBJECTS - EXCLUSIONS Clinically significant abnormalities on
chest radiograph Hepatitis B or C Recurrent Herpes Zoster Active
liver disease Previous unsuccessful treatment with an anti-TNF
agent
- Slide 40
- METHODS 73 centers in 17 countries 24 weeks Randomly assigned
to 1 of 3 treatment groups Received treatment every 4 weeks
- Slide 41
- METHODS 812 patients screened 623 patients enrolled Placebo n=
204 patients 189 patients completed Toc 4 mg/kg n=214 patients 186
patients completed Toc 8 mg/kg n=205 patients 191 patients
completed
- Slide 42
- METHODS Continued stable dose of MTX Received folic acid to
minimize any MTX toxicity During the study, patients could not
receive DMARDs other than MTX New doses of NSAIDs or oral
glucocorticoids
- Slide 43
- METHODS Patients were evaluated by Lab Values Physical
assessment Efficacy assessments Weeks 2, 4, 8, 12, 16, 20, and
24
- Slide 44
- METHODS Primary outcome measures 20% improvement in RA signs
and symptoms according to ACR criteria (ACR20 response) at 24
weeks
- Slide 45
- ACR20 Measure improvement in tender or swollen joint counts
Improvement in 3 of the 5 following: Acute phase reactant Patient
assessment Physician assessment Pain scale Disability/Functional
questionnaire 20% improvement
- Slide 46
- METHODS Secondary endpoints: ACR50 ACR70 Disease activity score
using 28 joint counts (DAS28) Remission < 2.6 Hemoglobin
concentrations ESR CRP mean concentrations Health Assessment
Questionnaire-Disability Index (HAQ-DI)
- Slide 47
- RESULTS 566 patients completed the study Primary outcome
analysis: ACR20 response Tocilizumab 4 mg/kg (n = 213) Tocilizumab
8 mg/kg (n = 205) Placebo (n = 204) Number of patients 102 (48%)120
(59%)54 (26%) p value vs placebo p < 0.0001 n/a
- Slide 48
- RESULTS Clinical response at week 24 Toc. 4 mg/kg (n = 213)
Toc. 8 mg/kg (n = 205) Placebo (n = 204) ACR50 Number of patients
76 (31%)90 (44%)22 (11%) p value vs placebo p < 0.001 n/a ACR70
Number of patients 26 (12%)45 (22%)4 (2%) p value vs placebo p <
0.001 n/a DAS 28